KRAS G13D mutation and sensitivity to cetuximab or panitumumab in a colorectal cancer cell line model

Gastrointestinal Cancer Research

Volumn 7, Issue 1, 2014, Pages 23-26

  Sree Kumar, Shalini ^a,b   Price, Timothy J ^a,b   Mohyieldin, Omar ^c   Borg, Matthew ^b   Townsend, Amanda ^a,b   Hardingham, Jennifer E ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND BAHRAIN   (Bahrain)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; PANITUMUMAB;

ARTICLE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CULTURE OPTIMIZATION; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; ONCOGENE K RAS;

EID: 84894592709     PISSN: 19347820     EISSN: 19347987     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Kohne CH, De Greve J, Hartmann JT, et al: Irinotecan combined with infusional 5-fluorouracil/ folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 19:920-926, 2008
2. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
3. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
4. Broadbridge VT, Karapetis CS, Price TJ: Cetuximab in metastatic colorectal cancer. Expert Rev Anticancer Ther 12:555-565, 2012
5. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643-2648, 2007
6. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007
7. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096, 2009
8. Oliner KS, Douillard J-Y, Siena S, et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). J Clin Oncol. 31, 2013 (abst 3511)
9. De Roock W, Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812-1820, 2010
10. Peeters M, Douillard JY, Van Cutsem E, et al: Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 31: 759-765, 2013
11. Saif MW, Kaley K, Chu E, Copur MS: Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin Colorectal Cancer 9:315-318, 2010
12. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007
13. Kurai J, Chikumi H, Hashimoto K, et al: Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 13:1552-1561, 2007
14. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, et al: Human IgG2 Antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 184:512-20, 2010
15. Metges J, Raoul J, Archour N, et al. PANERB study: panitumumab after cetuximab-based regimen failure. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol. 28, 2010 (abstr e14000).
16. Mao C, Huang YF, Yang ZY, et al: KRAS p. G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. Cancer 119:714-721, 2013
17. Guerrero S, Casanova I, Farre L, et al: K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60(suppl 15):6750-676, 2000
18. Klinger B, Sieber A, Fritsche-Guenther R, et al: Network quantification of EGFR signaling unveils potential for targeted combination therapy. Mol Syst Biol 9:1-14, 2013